BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 32710418)

  • 1. CRISPR Guide RNA Design Guidelines for Efficient Genome Editing.
    Schindele P; Wolter F; Puchta H
    Methods Mol Biol; 2020; 2166():331-342. PubMed ID: 32710418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Guide RNA Design Rules for Predicting Activity.
    Hiranniramol K; Chen Y; Wang X
    Methods Mol Biol; 2020; 2115():351-364. PubMed ID: 32006410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Heritable Mutations in Arabidopsis thaliana Using a Modified CRISPR/Cas9 Toolkit Comprising PAM-Altered Cas9 Variants and gRNAs.
    Yamamoto A; Ishida T; Yoshimura M; Kimura Y; Sawa S
    Plant Cell Physiol; 2019 Oct; 60(10):2255-2262. PubMed ID: 31198958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR-gRNA Design.
    Pallarès Masmitjà M; Knödlseder N; Güell M
    Methods Mol Biol; 2019; 1961():3-11. PubMed ID: 30912036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making point mutations in Escherichia coli BL21 genome using the CRISPR-Cas9 system.
    Wang X; He J; Le K
    FEMS Microbiol Lett; 2018 Jul; 365(14):. PubMed ID: 29596631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential Activation of Guide RNAs to Enable Successive CRISPR-Cas9 Activities.
    Clarke R; Terry AR; Pennington H; Hasty C; MacDougall MS; Regan M; Merrill BJ
    Mol Cell; 2021 Jan; 81(2):226-238.e5. PubMed ID: 33378644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precise Regulation of Cas9-Mediated Genome Engineering by Anti-CRISPR-Based Inducible CRISPR Controllers.
    Jain S; Xun G; Abesteh S; Ho S; Lingamaneni M; Martin TA; Tasan I; Yang C; Zhao H
    ACS Synth Biol; 2021 Jun; 10(6):1320-1327. PubMed ID: 34006094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Manipulation Using Fusion Guide RNAs for Cas9 and Cas12a.
    Shin HR; Kweon J; Kim Y
    Methods Mol Biol; 2021; 2162():185-193. PubMed ID: 32926383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering guide RNA to reduce the off-target effects of CRISPR.
    Wu J; Yin H
    J Genet Genomics; 2019 Nov; 46(11):523-529. PubMed ID: 31902584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.
    Kelkar A; Zhu Y; Groth T; Stolfa G; Stablewski AB; Singhi N; Nemeth M; Neelamegham S
    Mol Ther; 2020 Jan; 28(1):29-41. PubMed ID: 31601489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Assembly of CRISPR/Cas9 Lentiviral and rAAV Vectors for Targeted Genome Editing.
    Sandoval IM; Collier TJ; Manfredsson FP
    Methods Mol Biol; 2019; 1937():29-45. PubMed ID: 30706388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing.
    Li J; Hong S; Chen W; Zuo E; Yang H
    J Genet Genomics; 2019 Nov; 46(11):513-521. PubMed ID: 31911131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs.
    Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM
    Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.
    Hendel A; Bak RO; Clark JT; Kennedy AB; Ryan DE; Roy S; Steinfeld I; Lunstad BD; Kaiser RJ; Wilkens AB; Bacchetta R; Tsalenko A; Dellinger D; Bruhn L; Porteus MH
    Nat Biotechnol; 2015 Sep; 33(9):985-989. PubMed ID: 26121415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas systems: ushering in the new genome editing era.
    Perez Rojo F; Nyman RKM; Johnson AAT; Navarro MP; Ryan MH; Erskine W; Kaur P
    Bioengineered; 2018; 9(1):214-221. PubMed ID: 29968520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of genome editing through CRISPR-Cas9 engineering.
    Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF
    Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. gRNA-transient expression system for simplified gRNA delivery in CRISPR/Cas9 genome editing.
    Easmin F; Hassan N; Sasano Y; Ekino K; Taguchi H; Harashima S
    J Biosci Bioeng; 2019 Sep; 128(3):373-378. PubMed ID: 31010727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly multiplexed genome engineering using CRISPR/Cas9 gRNA arrays.
    Kurata M; Wolf NK; Lahr WS; Weg MT; Kluesner MG; Lee S; Hui K; Shiraiwa M; Webber BR; Moriarity BS
    PLoS One; 2018; 13(9):e0198714. PubMed ID: 30222773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CRISPR/CAS9, the King of Genome Editing Tools].
    Bannikov AV; Lavrov AV
    Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.